The SARS-CoV-2 pandemic has roused new enthusiasm for understanding the essential pathology of intense respiratory trouble disorder-Acute Respiratory Distress Syndrome (ARDS), which has been related with extreme coronavirus infection 2019 (Covid-19). ARDS has for quite some time been perceived to be strikingly heterogeneous, with a wide scope of causes as well as an expansive range of seriousness, variations from the norm on imaging, and gas-trade impairment.

References

1. Bellani G., et al. “Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries”. Journal of the American Medical Association8 (2016): 788-800.
2. Grasselli G., et al. “Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy”. Journal of the American Medical Association 16 (2020): 1574-1581.
3. Prescott HC., et al. “Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design”. American Journal of Respiratory and Critical Care Medicine 2 (2016): 147-155.
4. Ackermann M., et al. “Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19”. New England Journal of Medicine (2020).
5. Greene R., et al. “Pulmonary vascular obstruction in severe ARDS: angiographic alterations after i.v. fibrinolytic therapy”. American Journal of Roentgenology 3 (1987): 501-508.
6. Gattinoni L., et al. “COVID-19 pneumonia: different respiratory treatments for different phenotypes?” Intensive Care Medicine 6 (2020): 1099-1102.
7. The Acute Respiratory Distress Syndrome Network. “Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome”. New England Journal of Medicine18 (2000): 1301-1308.
8. Terpstra ML., et al. “Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis”. Critical Care Medicine 3 (2014): 691-700.
9. Iwashyna TJ., et al. “Implications of heterogeneity of treatment effect for reporting and analysis of randomized trials in critical care”. American Journal of Respiratory and Critical Care Medicine 9 (2015): 1045-1051.

Citation

Citation: Indranil Chatterjee., et al. “A Remarkably Heterogeneous Causes of Acute Respiratory Distress Syndrome (ards) Endotypes Associated with Covid-19". Acta Scientific Biotechnology 1.7 (2020): 23-24.

Copyright

Copyright: © 2020 Indranil Chatterjee., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.